BioMarin Pharmaceutical Inc. has announced its financial results for the third quarter of 2026, marking a significant milestone for the company. For the first time, BioMarin's quarterly revenue exceeded $1 billion, reaching $1.025 billion, which represents a 32% increase year-over-year. This growth is attributed to a 44% rise in revenues from metabolic conditions and a 12% increase from skeletal conditions.

Alexander Hardy, President and CEO of BioMarin, stated, “BioMarin delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therapeutics earlier this year and increased demand for our medicines from patients around the world.” Hardy also highlighted the addition of a new investigational treatment for Fabry disease, which could become the first subcutaneous enzyme therapy for this condition.

The company has updated its full-year guidance to reflect uncertainties regarding order timing and the impact of two acquired in-process research and development charges. Despite these challenges, BioMarin remains optimistic about its future growth, particularly with the potential launch of VOXZOGO for hypochondroplasia expected on May 30, 2027.

Background

BioMarin Pharmaceutical Inc., incorporated in Delaware, operates in the pharmaceutical preparations industry (SIC 2834). The company trades on the Nasdaq under the ticker BMRN. BioMarin focuses on developing and commercializing innovative biopharmaceuticals for serious diseases and medical conditions.

What the Filing Says

The SEC filing dated November 2, 2026, outlines the financial results for the third quarter ending September 30, 2026. It states, “On November 2, 2026, BioMarin Pharmaceutical Inc. announced financial results for its third quarter ended September 30, 2026.” The press release accompanying the filing details the company’s revenue growth and strategic initiatives.

Impact

This financial performance may positively affect various stakeholders, including investors, employees, and patients relying on BioMarin's treatments. The significant revenue growth and expansion of the product pipeline may enhance investor confidence and support employee morale amid ongoing development efforts.

What's Next

The filing does not specify what happens next, but it indicates that a conference call and webcast were scheduled for the same day to discuss the results further.